Critical issues in nephrology

Clinics in Chest Medicine

Volumn 24, Issue 4, 2003, Pages 561-581

  Peixoto, Aldo J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; CIDOFOVIR; CISPLATIN; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR; FENOLDOPAM; FOSCARNET; GOLD; HYPERTENSIVE AGENT; INTERLEUKIN 2; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PENICILLAMINE; PENTAMIDINE; TACROLIMUS; TICLOPIDINE; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; DIALYSIS; ELECTROLYTE DISTURBANCE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INTENSIVE CARE UNIT; ISCHEMIA; KIDNEY DISEASE; NEPHROLOGY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; TUMOR LYSIS SYNDROME;

EID: 0346363155     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00090-X     Document Type: Review

References (158)

1. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.
2. Guerin C, Girard R, Selli JM, Perdrix JP, Ayzac L. Initial versus delayed acute renal failure in the intensive care unit. A multicenter prospective epidemiological study. Rhone-Alps Area Study Group on Acute Renal Failure. Am J Respir Crit Care Med 2000;161:872-9.
3. Liano F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int Suppl 1998;66:S16-24.
4. Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000;11:1553-61.
5. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:1452-9.
6. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999;43:267-71.
7. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989;87:547-52.
8. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
9. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(Suppl 1):37-41.
10. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-82.
11. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997;17:27-33.
12. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-45.
13. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124:717-25.
14. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997;24:810-5.
15. Jeha S. Tumor lysis syndrome. Semin Hematol 2001;38:4-8.
16. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15:1505-9.
17. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997;103:363-7.
18. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980;68:486-91.
19. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94:133-9.
20. Schetz M. Non-renal indications for continuous renal replacement therapy. Kidney Int Suppl 1999;72: S88-94.
21. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001;38:13-21.
22. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64.
23. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-82.
24. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
25. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570-4.
26. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36.
27. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents - a new use for an old drug [comment]. N Engl J Med 2000;343:210-2.
28. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine [comment]. N Engl J Med 2000;343:180-4.
29. Curhan GC. Prevention of contrast nephropathy. JAMA 2003;289:606-8.
30. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-8.
31. Sandler CM. Contrast-agent-induced acute renal dysfunction - is iodixanol the answer? N Engl J Med 2003;348:551-3.
32. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-8.
33. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-9.
34. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int 1999;56:206-10.
35. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
36. Chamsuddin AA, Kowalik KJ, Bjarnason H, Dietz CA, Rosenberg MS, Gomes MD, et al. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy [erratum appears in AJR Am J Roentgenol 2002;179(6):1645]. AJR Am J Roentgenol 2002;179:591-6.
37. Chamsuddin AA, Kowalik KJ, Bjarnason H, Dietz CA, Rosenberg MS, Gomes MD, et al. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy [erratum appears in AJR Am J Roentgenol 2002;179(6):1645]. AJR Am J Roentgenol 2002;179:591-6.
38. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002;55:169-73.
39. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
40. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-6.
41. Peixoto AJ. Renal insufficiency. In: Spector SA, editor. Clinical companion: critical care. Philadelphia: Lippincott, Williams and Wilkins; 2000. p. 486-505.
42. Rabb H. Evaluation of urinary markers in acute renal failure. Curr Opin Nephrol Hypertens 1998;7:681-5.
43. Nolan III CR, Anger MS, Kelleher SP. Eosinophiluria - a new method of detection and definition of the clinical spectrum. N Engl J Med 1986;315:1516-9.
44. Ruffing KA, Hoppes P, Blend D, Cugino A, Jarjoura D, Whittier FC. Eosinophils in urine revisited. Clin Nephrol 1994;41:163-6.
45. Peixoto AJ, Birth, death and resurrection of the physical exam: clinical and academic perspectives on bedside diagnosis. Yale J Biol Med 2001;74:221-8.
46. Zarich S, Fang LS, Diamond JR. Fractional excretion of sodium. Exceptions to its diagnostic value. Arch Intern Med 1985;145:108-12.
47. Pru C, Kjellstrand CM. The FENa test is of no prognostic value in acute renal failure. Nephron 1984;36:20-3.
48. Miller TR, Anderson RJ, Linas SL, Henrich WL, Berns AS, Gabow PA, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med 1978;89:47-50.
49. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 2002;62:2223-9.
50. Kaplan AA, Kohn OF. Fractional excretion of urea as a guide to renal dysfunction. Am J Nephrol 1992;12:49-54.
51. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237-44.
52. Corwin HL, Krantz SB. Anemia of the critically ill: "acute" anemia of chronic disease. Crit Care Med 2000;28:3098-9.
53. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17.
54. Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999;27:2346-50.
55. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000;28:2773-8.
56. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288:2827-35.
57. Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997;23:288-96.
58. Faquim WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-94.
59. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001;59:246-51.
60. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001;16:932-8.
61. Finn WF. Recovery from acute renal failure. In: Molitoris BA, Finn WF, editors. Acute renal failure. Philadelphia: W.B. Saunders; 2001. p. 425-50.
62. Conger JD. Interventions in clinical acute renal failure: what are the data? Am J Kidney Dis 1995;26:565-76.
63. Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002;137:744-52.
64. Cantarovich F, Galli C, Benedetti L, Chena C, Castro L, Correa C, et al. High dose frusemide in established acute renal failure. BMJ 1973;4:449-50.
65. Kleinknecht D, Ganeval D, Gonzalez-Duque LA, Fermanian J. Furosemide in acute oliguric renal failure. A controlled trial. Nephron 1976;17:51-8.
66. Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981;15:90-6.
67. Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant 1997;12:2592-6.
68. Mehta RL, Pascual MT, Soroko S, Chertow GM, Group PS. Diuretics, mortality, and nonrecovery of renal function in acute renal failure [comment]. JAMA 2002;288:2547-53.
69. Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002;288:2599-601.
70. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
71. Juste RN, Moran L, Hooper J, Soni N. Dopamine clearance in critically ill patients. Intensive Care Med 1998;24:1217-20.
72. Galley HF. Renal-dose dopamine: will the message now get through? Lancet 2000;356:2112-3.
73. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526-31.
74. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group [comment]. Lancet 2000;356:2139-43.
75. Conger JD. A controlled evaluation of prophylactic dialysis in post-traumatic acute renal failure. J Trauma 1975;15:1056-63.
76. Gillum DM, Dixon BS, Yanover MJ, Kelleher SP, Shapiro MD, Benedetti RG, et al. The role of intensive dialysis in acute renal failure. Clin Nephrol 1986;25:249-55.
77. Gettings LG, Reynolds HN, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. Intensive Care Med 1999;25:805-13.
78. Mehta RL, Letteri JM. Current status of renal replacement therapy for acute renal failure. A survey of US nephrologists. The National Kidney Foundation Council on Dialysis. Am J Nephrol 1999;19:377-82.
79. Hyman A, Mendelssohn DC. Current Canadian approaches to dialysis for acute renal failure in the ICU. Am J Nephrol 2002;22:29-34.
80. van Bommel E, Ponssen HH. Intermittent versus continuous treatment for acute renal failure: where do we stand? Am J Kidney Dis 1997;30:S72-9.
81. Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000;36:294-300.
82. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001;60:777-85.
83. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001;60:1154-63.
84. Kellum JA, Angus DC, Johnson JP, Leblanc M, Griffin M, Ramakrishnan N, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002;28:29-37.
85. Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002;40:875-85.
86. Ronco C, Bellomo R, Ricci Z. Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant 2001;16(Suppl 5):67-72.
87. Phu NH, Hien TT, Mai NTH, Chau TTH, Chuong LV, Loc PP, et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med 2002;347:895-902.
88. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial [comment]. Lancet 2000;356:26-30.
89. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305-10.
90. Ronco C, Bellomo R, Kellum JA. Continuous renal replacement therapy: opinions and evidence. Adv Ren Replace Ther 2002;9:229-44.
91. Rodby RA. Hemofiltration for SIRS: bloodletting, twentieth century style? Crit Care Med 1998;26:1940-2.
92. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-53.
93. Sieberth HG, Kierdorf HP. Is cytokine removal by hemofiltration feasible? Kidney Int 1999;56:S79-83.
94. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, et al. A phase 11 randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
95. Bauer M, Marzi I, Ziegenfuss T, Riegel W. Prophylactic hemofiltration in severely traumatized patients: effects on post-traumatic organ dysfunction syndrome. Intensive Care Med 2001;27:376-83.
96. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999;27:2096-104.
97. Bellomo R, Tetta C, Brendolan A, Ronco C. Coupled plasma filtration adsorption. Blood Purif 2002;20:289-92.
98. Cole L, Bellomo R, Joumois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med 2001;27:978-86.
99. Gabow PA, Kaehny WD, Fennessey PV, Goodman SI, Gross PA, Schrier RW. Diagnostic importance of an increased serum anion gap. N Engl J Med 1980;303:854-8.
100. Roberts WL, Johnson RD. The serum anion gap. Has the reference interval really fallen? Arch Pathol Lab Med 1997;121:568-72.
101. Winter SD, Pearson JR, Gabow PA, Schultz AL, Lepoff RB. The fall of the serum anion gap. Arch Intern Med 1990;150:311-3.
102. Story DA, Poustie S, Bellomo R. Estimating unmeasured anions in critically ill patients: anion-gap, base-deficit, and strong-ion-gap. Anaesthesia 2002;57:1109-14.
103. Carvounis CP, Feinfeld DA. A simple estimate of the effect of the serum albumin level on the anion gap. Am J Nephrol 2000;20:369-72.
104. Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med 1998;26:1907-10.
105. Beck LH. Should the actual or the corrected serum sodium be used to calculate the anion gap in diabetic ketoacidosis? Cleve Clin J Med 2001;68:673-4.
106. Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000;117:260-7.
107. Adrogue HJ, Madias NE. Management of life-threatening acid-base disorders. First of two parts. N Engl J Med 1998;338:26-34.
108. Levy MM. An evidence-based evaluation of the use of sodium bicarbonate during cardiopulmonary resuscitation. Crit Care Clin 1998;14:457-83.
109. Viallon A, Zeni F, Lafond P, Venet C, Tardy B, Page Y, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Crit Care Med 1999;27:2690-3.
110. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002;15:23-9.
111. Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-46.
112. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23.
113. Shaer AJ, Rastegar A. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. A case report and review of the literature. Am J Nephrol 2000;20:332-8.
114. Jacobsen D. New treatment for ethylene glycol poisoning. N Engl J Med 1999;340:879-81.
115. Church AS, Witting MD. Laboratory testing in ethanol, methanol, ethylene glycol, and isopropanol toxicities. J Emerg Med 1997;15:687-92.
116. Megarbane B, Borron SW, Trout H, Hantson P, Jaeger A, Krencker E, et al. Treatment of acute methanol poisoning with fomepizole. Intensive Care Med 2001;27:1370-8.
117. Brent J, McMartin K, Phillips S, Aaron C, Kulig K. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001;344:424-9.
118. Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med 1999;340:832-8.
119. Baud FJ, Galliot M, Astier A, Bien DV, Garnier R, Likforman J, et al. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med 1988;319:97-100.
120. Porter GA. The treatment of ethylene glycol poisoning simplified. N Engl J Med 1988;319:109-10.
121. Hodgkin JE, Soeprono FF, Chan DM. Incidence of metabolic alkalemia in hospitalized patients. Crit Care Med 1980;8:725-8.
122. Anderson LE, Henrich WL. Alkalemia-associated morbidity and mortality in medical and surgical patients. South Med J 1987;80:729-33.
123. Adrogue HJ, Madias NE. Management of life-threatening acid-base disorders. Second of two parts. N Engl J Med 1998;338:107-11.
124. Mazur JE, Devlin JW, Peters MJ, Jankowski MA, Iannuzzi MC, Zarowitz BJ. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med 1999;27:1257-61.
125. Sadahiro T, Hirasawa H, Oda S, Shiga H, Nakanishi K, Kitamura N, et al. Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure. Crit Care Med 2001;29:1386-92.
126. Hsu SC, Wang MC, Liu HL, Tsai MC, Huang JJ. Extreme metabolic alkalosis treated with normal bicarbonate hemodialysis. Am J Kidney Dis 2001;37:E31.
127. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-9.
128. Choncol M, Berl T. Hyponatremia. In: Dubose Jr TD, Hamm LL, editors. Acid-base and electrolyte disorders. Philadelphia: Saunders; 2002. p. 229-39.
129. Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med 1987;83:905-8.
130. Kaczmarczyk G. Pulmonary-renal axis during positive-pressure ventilation. New Horiz 1994;2:512-7.
131. Kaczmarczyk G, Vogel S, Krebs M, Bunger H, Scholz A. Vasopressin and renin-angiotensin maintain arterial pressure during PEEP in nonexpanded, conscious dogs. Am J Physiol 1996;271:R1396-402.
132. Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol 1999;47:211-7.
133. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002;17:231-7.
134. Lane RM. SSRIs and hyponatraemia. Br J Clin Pract 1997;51:144-6.
135. Arinzon ZH, Lehman YA, Fidelman ZG, Krasnyansky II. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother 2002;36:1175-7.
136. Doyon S. The many faces of ecstasy. Curr Opin Pediatr 2001;13:170-6.
137. Cherney DZ, Davids MR, Halperin ML. Acute hyponatraemia and 'ecstasy': insights from a quantitative and integrative analysis. QJM 2002;95:475-83.
138. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999;281:2299-304.
139. Soupart A, Ngassa M, Decaux G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol 1999;51:383-6.
140. Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001;12(Suppl 17): S10-4.
141. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-91.
142. Polderman KH, Schreuder WO, Strack van Schijndel RJ, Thijs LG. Hypernatremia in the intensive care unit: an indicator of quality of care? Crit Care Med 1999;27:1105-8.
143. Palevsky PM, Bhagrath R, Greenberg A. Hypernatremia in hospitalized patients. Ann Intern Med 1996;124:197-203.
144. Sterns RH. Hypernatremia in the intensive care unit: instant quality - just add water. Crit Care Med 1999;27:1041-2.
145. Ethier JH, Kamel KS, Magner PO, Lemann Jr J, Halperin ML. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990;15:309-15.
146. Hamill RJ, Robinson LM, Wexler HR, Moote C. Efficacy and safety of potassium infusion therapy in hypokalemic critically ill patients. Crit Care Med 1991;19:694-9.
147. Kruse JA, Clark VL, Carlson RW, Geheb MA. Concentrated potassium chloride infusions in critically ill patients with hypokalemia. J Clin Pharmacol 1994;34:1077-82.
148. Sterns RH, Cox M, Feig PU, Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore) 1981;60:339-54.
149. Whang R, Whang DD, Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med 1992;152:40-5.
150. Nichols CG, Ho K, Hebert S. Mg(2+)-dependent inward rectification of ROMK1 potassium channels expressed in Xenopus oocytes. J Physiol 1994;476:399-409.
151. Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999;10:1616-22.
152. Agusti AG, Torres A, Estopa R, Agustividal A. Hypophosphatemia as a cause of failed weaning: the importance of metabolic factors. Crit Care Med 1984;12:142-3.
153. Aubier M, Murciano D, Lecocguic Y, Viires N, Jacquens Y, Squara P, et al. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med 1985;313:420-4.
154. Davis SV, Olichwier KK, Chakko SC. Reversible depression of myocardial performance in hypophosphatemia. Am J Med Sci 1988;295:183-7.
155. Vered Z, Battler A, Motro M, Frank M, Inbar R, Neufeld HN. Left ventricular function in patients with chronic hypophosphatemia. Am Heart J 1984;107:796-8.
156. Marik PE, Bedigian MK. Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study. Arch Surg 1996;131:1043-7.
157. Hayek ME, Eisenberg PG. Severe hypophosphatemia following the institution of enteral feedings. Arch Surg 1989;124:1325-8.
158. Laaban JP, Grateau G, Psychoyos I, Laromiguiere M, Vuong TK, Rochemaure J. Hypophosphatemia induced by mechanical ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med 1989;17:1115-20.